Mr. Clark is a Partner in Palladium Equity Partners, a private equity firm based in New York, NY. Mr. Clark serves on the Board of Directors of several Palladium portfolio companies as well as the firm’s investment and management committees. He currently leads the firm’s Industrial team. Previously he was a Vice President at Windjammer Capital Investors where he sourced, analyzed and structured investments in a range of industries. Before joining Windjammer, Mr. Clark was an Associate at Genstar Capital, a San Francisco based private equity investment firm. Prior to Genstar, Mr. Clark was an investment banking analyst at Deutsche Banc Alex Brown. Mr. Clark received his B.A. from Middlebury College, where he double majored in political science and economics, and an M.B.A. from Columbia Business School.
Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc., a private company utilizing DNA repair technology licensed from Yale University to treat patients with genetically-based diseases. Mr. DeWahl is also a co-founder of Life Science Pharmaceuticals, Inc., which is developing novel therapeutics to treat cancer, diabetes and other serious illnesses based on IP licensed from The Ludwig Institute for Cancer Research, Memorial Sloan Kettering, Dana Farber and other major academic research institutions.
Prior to his experience in the biopharmaceutical industry, Mr. DeWahl was an investment banker focused on the health care and life sciences industry for over 25 years, including positions as a Managing Director at Prudential Securities, Oppenheimer and Co., Vector Securities and Life Science Group. Mr. DeWahl has successfully raised capital and/or advised on corporate partnerships for numerous companies with biopharmaceutical and other life science products currently on the market, including Tarceva® (Roche/Genentech), Byetta® (Bristol-Myers/Amylin), Synvisc® (Sanofi/Genzyme), Adagen® (Enzon) and WinRho® (Cangene).
Mr. DeWahl received his BA in economics from the University of Wisconsin and his MBA in finance from Columbia University.
Dr. Stern joined the Company on January 1, 2022. He was previously Corporate Vice President and Global Therapeutic Area (TA) Head Medicine (Virology and Infectious Diseases) at Boehringer Ingelheim (BI) Pharmaceuticals for more than 15 years. As the TA Head, he was responsible for the development strategy and implementation of all clinical development projects within the therapeutic area. He has a strong track record of success leading teams from early concepts through preclinical and clinical phases (1 – 4) of development which led to numerous INDs, several NDAs, sNDAs and MAA’s.
He has had extensive experience with regulatory authorities as the primary clinical representative for all FDA and EMA interactions in the TA. He served for many years as a senior member of the BI International Medical Committee which provided governance of all clinical development activities across seven major therapeutic areas.
Dr. Stern received his M.D. from the Albert Einstein College of Medicine in New York where he spent an additional 4 years in laboratory research in pharmacology and biochemistry. He received his medical training (Internal Medicine and Gastroenterology) at New York University Medical Center/Bellevue Hospital, NY, NY. He was on the faculty, specializing in GI Endoscopy, for more than twenty years before joining the Pharmaceutical R&D sector.
